Sign inJoin waitlistJoin the waitlist

Jordan Berlin

And Director, Phase I Program · Vanderbilt University Medical Center

Credentials: · · ·

History

Vanderbilt University Medical Center
Present
Vanderbilt University Medical Center
Present

University of Wisconsin School of Medicine and Public Health
1993–1995
Internal Medicine
University of Cincinnati
1989–1992
University of Illinois College of Medicine
1985–1989

Research

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
New England Journal of Medicine · 2004 · 8,376 citations
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
New England Journal of Medicine · 2017 · 2,601 citations
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations

Dana Cardin
28 papers · 1 as a fellow
Laura Goff
23 papers · 1 as a fellow
Al Benson
22 papers
Mace Rothenberg
21 papers
SD
Satya Das
21 papers · 9 as a fellow
Craig Lockhart
16 papers · 8 as a fellow
Mary Washington
13 papers
Chanjuan Shi
11 papers
EC
Emily Chan
11 papers
Kristen Ciombor
11 papers · 4 as a fellow
Bruce Minsky
10 papers
Wells Messersmith
10 papers

Grants

Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer
National Cancer Institute · P50
Project lead · $2.2M · Vanderbilt University Medical Center
2019–2025
Vanderbilt Network Lead Academic Participating Site for the NCTN
National Cancer Institute · UG1
Contact PI · $1.9M · Vanderbilt University Medical Center
2019–2025
Mdacc-Predict
National Cancer Institute · U24
PI · $1.3M · University of Tx Md Anderson Can Ctr
2018–2023
Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials Consortium
National Cancer Institute · UM1
PI · $732.4K · Yale University
2014–2020

Clinical trials

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2020–2027
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Principal investigator · Withdrawn · Phase 1
Vanderbilt-Ingram Cancer Center
2017–2020
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Principal investigator · Completed · Phase 1, Phase 2
Vanderbilt-Ingram Cancer Center
2017–2023
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
Principal investigator · Terminated · Phase 1, Phase 2
Symphogen A/S
2016–2019